Medicus Pharma (MDCX) Income from Continuing Operations (2024 - 2025)

Medicus Pharma (MDCX) reported Income from Continuing Operations of 7790600.0 for Q4 2025, down 117.28% on a YoY basis from 45074566.45 in Q4 2024, and down 51937233.33% quarter-over-quarter from 15.0 in Q3 2025.

Medicus Pharma (MDCX) Income from Continuing Operations (2024 - 2025) Analysis & Trends

Medicus Pharma has reported Income from Continuing Operations for 2 years, with the latest figure at 7790600.0 in Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 117.28% year-over-year to 7790600.0; the trailing twelve-month figure through Dec 2025 stood at 18909111.0 (down 69.12% YoY), and the FY2025 full-year result was 34359302.0, down 208.0% from the prior year.
  • Income from Continuing Operations for Q4 2025 stood at 7790600.0, down from 15.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 15.0 in Q3 2025, with the low at 7790600.0 in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 3.30 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn 5.24 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 697.00 Mn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -4.21 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 2.02 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 2.71 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 2.68 Bn
10 Medicus Pharma 7.87 Mn 7.98 Mn - -7.79 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.79 Mn
Sep 30, 2025 -15.00
Jun 30, 2025 -6.02 Mn
Mar 31, 2025 -5.10 Mn
Dec 31, 2024 -3.59 Mn
Sep 30, 2024 -2.33 Mn
Jun 30, 2024 -3.55 Mn
Mar 31, 2024 -1.71 Mn